

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ
日本腎臓学会		丸山彰一	エビデンスに基づくCKD診療ガイドライン2023	東京医学社	東京	2023	
日本腎臓学会		丸山彰一	CKD診療ガイド2024	東京医学社	東京	2024	
山縣邦弘	急速進行性糸球体腎炎	矢崎義雄他	内科学第12版	朝倉書店	東京	2022	IV-61-65
山縣邦弘	抗糸球体基底膜抗体病 (Goodpasture症候群)	矢崎義雄他	内科学第12版	朝倉書店	東京	2022	IV-107
要 伸也	多職種連携によるCKM：腎臓病療養指導士の役割	「AMED長寿科学研究開発事業高齢腎不全患者に対する腎代替療法の開始/見合わせの意思決定プロセスと最適な緩和医療・ケア構築研究班」	高齢腎不全患者のための保存的腎臓療法-conservative kidney management (CKM)の考え方と実践-	東京医学社	東京	2022年	Page186-189
要 伸也 (監修)		厚生労働科学研究費補助金（腎疾患政策研究事業）慢性腎臓病（CKD）患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究班	CKD ケアのための多職種連携マニュアル	東京医学社		2023年3月24日	100ページ
岡田浩一、他	最新ガイドラインに基づく腎・透析診療指針2023-24序文、腎画像診断	岡田浩一	最新ガイドラインに基づく腎・透析診療指針2023-24	総合医学社	東京	2023	22
岡田浩一、他	第13章高齢者CKD	丸山彰一	エビデンスに基づくCKD診療ガイドライン2023	東京医学社	東京	2023	149

岡田浩一	第1章3CKD：標準治療の理解と実践	南学正臣、高野秀樹	腎臓内科診療の掟	中外医学社	東京	2023	17
黒澤陽一、成田一衛	薬剤性腎障害	岡田浩一	最新ガイドラインに基づく腎・透析診療指針 2023-24	総合医学社	東京	2023	63-69
藤井美里、成田一衛	MPGN (C3腎症)：わかってきた新しい病型分類と概念	南学正臣、高野秀樹	腎臓内科診療の掟	中外医学社	東京	2023	129-134
旭浩一	尿検査(蛋白尿・血尿)	岡田浩一	最新ガイドラインに基づく腎・透析診療指針	総合医学社	東京	2023	7-13
栗原孝成	薬剤性腎障害	福井次矢、高木 誠、小室一成	今日の治療指針 2024年版	医学書院	東京	2024	616-618
栗原孝成	がんと腎臓	今井圓裕、丸山彰一、猪阪善隆	腎臓内科レジデントマニュアル	医学書院	東京	2023	641-649
川嶋聡子、要 伸也	ANCA検査のピットフォール		SRL宝函44(2)			2023	42-44

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Ikeda A, Fujii M, Ohno Y, Godai K, Li Y, Nakamura Y, Yabe D, Tsushita K, Kashiwara N, Kamide K, Kabayama M.	Effect of the Diabetic Nephropathy Aggravation Prevention Program on medical visit behavior in individuals under the municipal national health insurance.	J Diabetes Investig.	Online ahead of print	Online ahead of print	Online ahead of print
Handa M, et al.	The prevalence of locomotive syndrome and its associated factors in patients with Type 2 diabetes mellitus.	Mod Rheumatol.	33(2)	422-427	2023

Kanda E, Epureanu BI, Adachi T, Kashihara N.	Machine-learning-based Web system for the prediction of chronic kidney disease progression and mortality.	PLOS Digit Health.	2(1)	e0000188	2023
Fujii M, Ohno Y, Ikeda A, Godai K, Li Y, Nakamura Y, Yabe D, Tsushita K, Kashihara N, Kamide K, Kabayama M.	Current status of the rapid decline in renal function due to diabetes mellitus and its associated factors: analysis using the National Database of Health Checkups in Japan.	Hypertens Res.	Online ahead of print.		2023
Okuda Y, Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Sawanobori T, Taguri M.	The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial.	Hypertens Res.	46(2)	437-444.	2023
Sugawara Y, et al.	Genome-wide association study of the risk of chronic kidney disease and kidney-related traits in the Japanese population: J-Kidney-Biobank.	J Hum Genet.	68(2)	55-64	2023
Asahina Y, Sakaguchi Y, Kajimoto S, Hattori K, Oka T, Kashihara N, Isaka Y.	A Randomized Controlled Trial of Whole-Body Vibration on Gait Ability and Balance among Older Hemodialysis Patients.	Clin J Am Soc Nephrol.	18(1)	84-90	2023
Jongs N, et al.	Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD.	J Am Soc Nephrol.	33(11)	2094-2107	2022
Tsuboi N, et al.	Chronic kidney disease and clinical outcomes in patients with COVID-19 in Japan.	Clin Exp Nephrol.	26(10)	974-981	2022
Nakagawa N, Maruyama S, Kashihara N, Narita I, Isaka Y.	New-onset and relapse of nephrotic syndrome following COVID-19 vaccination: a questionnaire survey in Japan.	Clin Exp Nephrol.	26(9)	909-916	2022

Yano Y, et al.	The associations of the national health and productivity management program with corporate profits in Japan.	Epidemiol Health.	44	e2022080	2022
Nangaku M, Takama H, Ichikawa T, Mukai K, Kojima M, Suzuki Y, Watada H, Wada T, Ueki K, Kashihara N, Kadowaki T, Hase H, Akizawa T.	Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: Design and baseline characteristics of AYAME study.	Nephrol Dial Transplant.	Online ahead of print.	gfac242.	2022
Kimura T, Nishino T, Sobajima H, Akahori T, Ito T, Terada Y, Katafuchi R, Fujimoto S, Okada H, Mimura T, Suzuki S, Saka Y, Sofue T, Kitagawa K, Fujita Y, Mizutani M, Kashihara N, Sato H, Narita I, Isaka Y.	Deep learning analysis of clinical course of primary nephrotic syndrome: Japan Nephrotic Syndrome Cohort Study (JNSCS).	Clin Exp Nephrol.	26(12)	1170-1179	2022
Sugawara Y, Hirakawa Y, Mise K, Kashiwabara K, Hanai K, Yamaguchi S, Katayama A, Onishi Y, Yoshida Y, Kashihara N, Matsuyama Y, Babazono T, Nangaku M, Wada J.	Analysis of inflammatory cytokines and estimated glomerular filtration rate decline in Japanese patients with diabetic kidney disease: a pilot study.	Biomark Med.	16(10)	759-770	2022

James G, Garcia Sanchez JJ, Carrero JJ, Kumar S, Pecoits-Filho R, Heerspink HJL, Nolan S, Kanda E, Kashihara N, Arnold M, Kosiborod MN, Lainscak M, Pollock C, Wheeler DC.	Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility.	Kidney Int Rep.	7(9)	2059-2070	2022
Kihara M, Yokoo T, Kashihara N, Narita I, Suzuki Y.	Correction to: Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan.	Clin Exp Nephrol.	26(4)	323-324	2022
Matsuzaki K, Aoki R, Nihei Y, Suzuki H, Kihara M, Yokoo T, Kashihara N, Narita I, Suzuki	Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan.	Clin Exp Nephrol.	26(4)	316-322	2022
Nakagawa N, et al.	Knowledge of Chronic Kidney Disease among the General Population: A Questionnaire Survey in Hokkaido Prefecture, Japan	J Pers Med.	12(11)	1837	2022
Kimura Y, Yamamoto R, Shinzawa M, Aoki K, Tomi R, Ozaki S, Yoshimura R, Shimomura A, Iwatani H, Isaka Y, Iseki K, Tsuruya K, Fujimoto S, Narita I, Konta T, Kondo M, Kasahara M, Shibasaki Y	Alcohol Consumption and a Decline in Glomerular Filtration Rate: The Japan Specific Health Checkups Study.	Nutrients	15(6)	1540	2023
中川 直樹	DKD進行予防の観点からの他科連携、多職種連携の必要性	Progress in Medicine	43(2)	161-165	2023
田中文隆、旭浩一	岩手県の取り組み	JKA Newsletter	第13号 (2023年2月発刊)	4-5	2023年

Kosugi T, et al.	Height loss is associated with decreased kidney function: The Japan Specific Health Checkups (J-SHC) Study.	Geriatr Gerontol Int.	23(4)	282-288	2023
Iwasaki T, et al.	Association between height loss and mortality in the general population.	Sci Rep.	13(1)	3593	2023
Harada T, Nagai K, Mase K, Tsunoda R, Iseki K, Moriyama T, Tsuruya K, Fujimoto S, Narita I, Konta T, Kondo M, Kasahara M, Shibagaki Y, Asahi K, Watanabe T, Yamagata K.	Elevated Crude Mortality in Obese Chronic Kidney Disease Patients with Loss of Exercise Habit: A Cohort Study of the Japanese General Population.	Intern Med.	Epub ahead of print		2022
Nishitani N, Kosaki K, Matsui M, Sugaya T, Kuro-O M, Saito C, Yamagata K, Maeda S.	Association between trunk flexibility and renal flow pulsatility in middle-aged and older adults.	Exp Gerontol.	Epub ahead of print		2022
Yamagata K.	Trends in the incidence of kidney replacement therapy: comparisons of ERA, USRDS, and Japan registries.	Nephrol Dial Transplant.	38(4)	797-799	2023
Nagai K, Sairenchi T, Yamagata K, Yamagishi K, Iso H, Irie F.	High Estimated Glomerular Filtration Rate and Risk of Cancer Mortality in a Japanese Cohort Study: The Ibaraki Prefectural Health Study.	JMA J.	5(4)	546-550	2022
Wakasugi M, Narita I, Iseki K, Asahi K, Yamagata K, Fujimoto S, Moriyama T, Konta T, Tsuruya K, Kasahara M, Shibagaki Y, Kondo M, Watanabe T; Japan Specific Health Checkups (J-SHC) Study Group.	Healthy Lifestyle and Incident Hypertension and Diabetes in Participants with and without Chronic Kidney Disease: The Japan Specific Health Checkups (J-SHC) Study.	Intern Med.	61(19)	2841-2851	2022

Kimura H, et al.	Health-related behavioral changes and incidence of chronic kidney disease: The Japan Specific Health Checkups (J-SHC) Study.	Sci Rep.	12(1)	16319	2022
Otaki Y, et al.	A Body Shape Index and Aortic Disease-Related Mortality in Japanese General Population.	J Atheroscler Thromb.	Epub ahead of print		2022
Yoshioka M, Kosaki K, Matsui M, Mori S, Nishitani N, Saito C, Yamagata K, Kuro-O M, Maeda S.	Association between the intake of plant and animal proteins and the serum fibroblast growth factor-23 level in patients with chronic kidney disease analyzed by the isocaloric substitution model.	Endocr J.	70(1)	31-42	2023
Kawano K, Otaki Y, Suzuki N, Fujimoto S, Iseki K, Moriyama T, Yamagata K, Tsuruya K, Narita I, Kondo M, Shibagaki Y, Asahi K, Watanabe T, Konta T.	Prediction of mortality risk of health checkup participants using machine learning-based models: the J-SHC study.	Sci Rep.	12(1)	14154	2022
Mori S, Tarumi T, Kosaki K, Matsui M, Yoshioka M, Sugawara J, Kuro-O M, Saito C, Yamagata K, Maeda S.	Effects of the number of sit-stand maneuver repetitions on baroreflex sensitivity and cardiovascular risk assessments.	Am J Physiol Regul Integr Comp Physiol.	322(5)	R400-R410	2022
Yoshioka M, Kosaki K, Noma S, Matsui M, Kuro-O M, Shibata A, Saito C, Yamagata K, Oka K, Maeda S.	Daily behavioral and sleep patterns are associated with aging-induced male-specific disorders in individuals with reduced renal function.	Exp Gerontol.	161	111717	2022

Okubo R, Hoshi SL, Kimura T, Kondo M, Asahi K, Iseki C, Fujimoto S, Narita I, Nishiyama H, Yamagata K, Iseki K.	Cost-effectiveness of mass screening for dipstick hematuria in Japan.	Clin Exp Nephrol.	26(5)	398-412	2022
今澤俊之、浅沼克彦、寺脇博之、日比野久美子、入江康文	千葉県における慢性腎臓病（CKD）重症化予防対策-CKD対策協力医制度の現状報告	千葉県医師会雑誌	第74巻6号	P256-260	2022
Imasawa T, Saito C, Kai H, et.al.	Long-term effectiveness of a primary care practice facilitation program for chronic kidney disease management: an extended follow-up of a cluster-randomized FROM-J study.	Nephrol Dial Transplant.	38(1)	158-166	2023
Hibino M, et al.	Blood Pressure, Hypertension, and the Risk of Aortic Dissection Incidence and Mortality: Results From the J-SCH Study, the UK Biobank Study, and a Meta-Analysis of Cohort Studies	Circulation	145(9)	633-44	2022
Hosojima M, Kabasawa H, Kaseda R, Ishikawa-Tanaka T, Obi Y, Murayama T, Kuwahara S, Suzuki Y, Narita I, Saito A	Efficacy of Low-Protein Rice for Dietary Protein Restriction in CKD Patients: A Multicenter, Randomized, Controlled Study	Kidney360	3(11)	1861-70	2022
Kabasawa K, Hosojima M, Ito Y, Matsushima K, Tanaka J, Hara M, Nakamura K, Narita I, Saito A	Association of metabolic syndrome traits with urinary biomarkers in Japanese adults	Diabetol Metab Syndr	14(1)	9	2022
Kabasawa K, Takachi R, Nakamura K, Sawada N, Tsugane S, Ito Y, Tanaka J, Narita I, Matsushita K	Associations of Urinary and Dietary Sodium-To-Potassium Ratios with Albuminuria in Community-Dwelling Japanese Adults: A Cross-Sectional Study	Kidney Blood Press Res	47(9)	576-85	2022

Kawano K, et al.	Prediction of mortality risk of health checkup participants using machine learning-based models: the J-SHC study	Sci Rep	12(1)	14154	2022
Kimura H, et al.	Health-related behavioral changes and incidence of chronic kidney disease: The Japan Specific Health Checkups (J-SHC) Study	Sci Rep	12(1)	16319	2022
Okubo R, Hoshi SL, Kimura T, Kondo M, Asahi K, Iseki C, Fujimoto S, Narita I, Nishiyama H, Yamagata K, Iseki K	Correction to: Cost-effectiveness of mass screening for dipstick hematuria in Japan	Clin Exp Nephrol	26(5)	413-4	2022
Okubo R, Kondo M, Hoshi SL, Kai H, Saito C, Iseki K, Iseki C, Watanabe T, Narita I, Matsuo S, Makino H, Hishida A, Yamagata K	Behaviour modification intervention for patients with chronic kidney disease could provide a mid- to long-term reduction in public health care expenditure: budget impact analysis	Clinical and Experimental Nephrology	26(6)	601-611	2022
Wakasugi M, Kazama JJ, Nitta K, Narita I	Smoking and risk of fractures requiring hospitalization in haemodialysis patients: a nationwide cohort study in Japan	Nephrol Dial Transplant	37(5)	950-9	2022
Wakasugi M, Narita I, Iseki K, Asahi K, Yamagata K, Fujimoto S, Moriyama T, Konta T, Tsuruya K, Kasahara M, Shibagaki Y, Kondo M, Watanabe T	Healthy Lifestyle and Incident Hypertension and Diabetes in Participants with and without Chronic Kidney Disease: The Japan Specific Health Checkups (J-SHC) Study	Internal Medicine	61(19)	2841-2851	2022
Wakasugi M, Yokoseki A, Wada M, Momotsu T, Sato K, Kawashima H, Nakamura K, Onodera O.	Polypharmacy, chronic kidney disease, and incident fragility fracture: a prospective cohort study	J Bone Miner Metab	40(1)	157-66	2022

Wakasugi M, Yokoseki A, Wada M, Sanpei K, Momotsu T, Sato K, Onodera O, Narita I	Stroke incidence and chronic kidney disease: A hospital-based prospective cohort study	Nephrology (Carlton)	27(7)	577-87	2022
Wakasugi M, Narita I.	Prefecture-specific prevalence of overweight/obesity is associated with regional variation in the incidence of treated ESKD in Japan.	Clin Exp Nephrol.	27(2)	132-140	2023
Wakasugi M, Narita I.	Trends in the incidence of renal replacement therapy by type of primary kidney disease in Japan, 2006-2020.	Nephrology (Carlton).	28(2)	119-129	2023
Wakasugi M, Narita I.	Birth cohort effects in incident renal replacement therapy in Japan, 1982-2021.	Clin Exp Nephrol.	doi: 10.1007/s10157-023-02345-x.		2023
内田治仁	特集：腎疾患対策検討会報告書の進捗と課題 普及啓発活動の進捗と課題	腎臓内科	第16巻6号	656-661	2022
伊藤孝史、内田治仁、柏原直樹	NPO法人日本腎臓病協会	腎臓内科	第16巻6号	738-745	2022
Ikeuchi H, Sugiyama H, Mukoyama M, et al.	A nationwide analysis of renal and patient outcomes for adults with lupus nephritis in Japan..	Clin. Exp. Nephrol.	26 (9)	898-908	2022
Imasawa T, Saito C, Mukoyama M, et al.	Long-term effectiveness of a primary care practice facilitation program for chronic kidney disease management: an extended follow-up of a cluster-randomized FROM-J study.	Nephrol. Dial. Transplant.	38 (1)	158-166	2023
Shibata S, Mukoyama M, Rakugi H, et al.	COVID-19 pandemic and hypertension: an updated report from the Japanese Society of Hypertension project team on COVID-19.	Hypertens. Res.	46 (3)	589-600	2023

Matsumoto C, Shibata S, Mukoyama M, et al.	Long COVID and hypertension-related disorders: a report from the Japanese Society of Hypertension Project Team on COVID-19.	Hypertens. Res.	46 (3)	601-619	2023
Okadome Y, Kuwabara T, et al.	Increased numbers of pre-operative circulating monocytes predict risk of developing cardiac surgery-associated acute kidney injury in conditions requiring cardio pulmonary bypass.	Clin Exp Nephrol.	27 (4)	329-339	2023
栗原孝成	腎臓症候群 IIIX 中毒性腎障害「抗腫瘍薬による腎障害」	別冊 日本臨牀	25	291-292	2022
栗原孝成	特集 Onco-nephrology: 悪性腫瘍治療と腎機能障害「分子標的薬による腎障害: 病態と対策 低分子化合物」	腎と透析	92 (3)	614-617	2022
栗原孝成	透析患者における血清 calprotectin (MRP8/14) の臨床的意義と機能的メカニズムの解明	日本透析医会雑誌	37 (2)	279-282	2022
栗原孝成	Onconeurology ～がん免疫療法と腎障害を中心に	秋田腎不全研究会誌	25	9-14	2022
栗原孝成	特集 腎臓と免疫 update 免疫が深く関与する腎臓病・腎障害 「がん免疫療法と腎障害」	腎臓内科	16 (4)	419-425	2022
Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S	Effectiveness and current status of multidisciplinary care for patients with chronic kidney disease in Japan: a nationwide multicenter cohort study.	Clin Exp Nephrol	doi: 10.1007/s10157-023-02338-w. Online ahead of print.		2023 Mar 31
要 伸也	多職種協働によるキャリア支援 資格創設による看護職への期待	臨床透析	38巻11号	Page1420-1425	2022
要 伸也	特集/腎疾患対策検討会 報告書の進捗と課題: 人材育成の進捗と課題	腎臓内科	16巻第6号	Page417-422	2022

要 伸也	CKMにおける多職種連携の重要性	腎臓内科	15巻第4号	Page676-681	2022
Okada H, et al.	Development of a prognostic risk score to predict early mortality in incident elderly Japanese hemodialysis patients.	PLoS One.	19(4)	e0302101.	2024
Yano Y, et al.	Kidney outcomes associated with hematuria and proteinuria trajectories among patients with IgA nephropathy in real-world clinical practice: The Japan Chronic Kidney Disease Database	Nephrology	29	65-75	2023
岡田浩一	腎不全患者の予後と予測式の開発	日本腎臓学会誌	65	876-879	2023
岡田浩一、他	腎臓病領域における20年のあゆみと今後の展望	日本内科学会創立120周年記念誌	特別号	209	2023
Matsuzaki K, et al.	Current treatment status of IgA nephropathy in Japan: a questionnaire survey.	Clin Exp Nephrol	(in press)	(in press)	(in press)
Yamamoto T, Kasahara M, Ueshima K, Uemura S, Kashihara N, Kimura K, Konta T, Shoji T, Mima A, Mukoyama M, et al.	Multicenter randomized controlled trial of intensive uric acid lowering therapy for CKD patients with hyperuricemia: TARGET-UA.	Clin Exp Nephrol.			2024 Online ahead of print.
Kishi S, Nakashima T, Goto T, Nagasu H, Brooks CR, Okada H, Tamura K, Nakano T, Narita I, Maruyama S, Yano Y, Yokoo T, Wada T, Wada J, Nangaku M, Kashihara N.	Association of serum magnesium levels with renal prognosis in patients with chronic kidney disease.	Clin Exp Nephrol.			2024 Online ahead of print.

Yusei O, Nagasu H, Nakagawa N, Terawaki S, Moriwaki T, Itano S, Kishi S, Sasaki T, Kashihara N, Ohsugi T.	A case series of Fabry diseases with CKD in Japan.	Clin Exp Nephrol.			2024 Online ahead of print.
Kanda E, Epureanu BI, Adachi T, Sasaki T, Kashihara N.	Mathematical expansion and clinical application of chronic kidney disease stage as vector field.	PLoS One.	19(3)	e0297389.	2024
Kishi S, Nagasu H, Kidokoro K, Kashihara N.	Oxidative stress and the role of redox signalling in chronic kidney disease.	Nat Rev Nephrol.	20(2)	101-119.	2024
Yanagita M, et al.	Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022.	Clin Exp Nephrol.	28(2)	85-122.	2024
Sugawara Y, Kanda E, Ohsugi M, Ueki K, Kashihara N, Nangaku M.	eGFR slope as a surrogate endpoint for end-stage kidney disease in patients with diabetes and eGFR > 30 mL/min/1.73 m ² in the J-DREAMS cohort.	Clin Exp Nephrol.	28(2)	144-152.	2024
Kanda E, Epureanu BI, Adachi T, Sasaki T, Kashihara N.	New marker for chronic kidney disease progression and mortality in medical-word virtual space.	Sci Rep.	14(1)	1661.	2024
Hirano A, Kadoya H, Yamanouchi Y, Kishi S, Sasaki T, Kashihara N.	IL-1 β may be an indicator of peritoneal deterioration after healing of peritoneal dialysis-associated peritonitis.	BMC Nephrol.	24(1)	374.	2023

Li Y, Fujii M, Ohno Y, Ikeda A, Godai K, Nakamura Y, Akagi Y, Yabe D, Tsushita K, Kashihara N, Kamide K, Kabayama M.	Lifestyle factors associated with a rapid decline in the estimated glomerular filtration rate over two years in older adults with type 2 diabetes-Evidence from a large national database in Japan.	PLoS One.	18(12)	e0295235.	2023
Kurasawa S, Yasuda Y, Kato S, Maruyama S, Okada H, Kashihara N, Narita I, Wada T, Yamagata K; REACH-J CKD collaborators.	Relationship between the lower limit of systolic blood pressure target and kidney function decline in advanced chronic kidney disease: an instrumental variable analysis from the REACH-J CKD cohort study.	Hypertens Res.	46(11)	2478-2487.	2023
Kidokoro K, Kadoya H, Cherney DZI, Kondo M, Wada Y, Umeno R, Kishi S, Nagasu H, Nagai K, Suzuki T, Sasaki T, Yamamoto M, Kanwar YS,	Insights into the Regulation of GFR by the Keap1-Nrf2 Pathway.	Kidney360.	4(10)	1454-1466.	2023
Itano S, Kanda E, Nagasu H, Nangaku M, Kashihara N.	eGFR slope as a surrogate endpoint for clinical study in early stage of chronic kidney disease: from The Japan Chronic Kidney Disease Database.	Clin Exp Nephrol.	27(10)	847-856.	2023
Kadoya H, Hirano A, Umeno R, Kajimoto E, Iwakura T, Kondo M, Wada Y, Kidokoro K, Kishi S, Nagasu H, Sasaki T, Taniguchi S, Takahashi M, Kashihara N.	Activation of the inflammasome drives peritoneal deterioration in a mouse model of peritoneal fibrosis.	FASEB J.	37(9)	e23129.	2023

Koshino A, Schechter M, Chertow GM, Vart P, Jongs N, Toto RD, Rossing P, Correa-Rotter R, McMurray JJV, Górriz JL, Isidto R, Kashihara N, Langkilde AM, Wheeler DC,	Dapagliflozin and Anemia in Patients with Chronic Kidney Disease.	NEJM Evid.	2(6)	EVIDoa2300049.	2023
柏原直樹, 岸誠司, 山内佑, 山本稔也.	J-CKD-DBが解き明かすSGLT2阻害薬の腎保護効果.	糖尿病・内分泌代謝科	56(4)	386-394.	2023
城所研吾, 柏原直樹.	腎臓病研究におけるイメージング技術の進歩を展望.	日本腎臓学会誌	65(8)	942-950.	2023
渡邊昌, 柏原直樹.	慢性腎臓病進行をいかに予防するかThe International Workshop on Dietary Therapy for Chronic Kidney Diseaseを踏まえて.	アンチ・エイジング医学	19(5)	430-436	2023
柏原直樹, 岸誠司, 山内佑, 山本稔也.	リアルワールドデータからみた糖尿病性腎臓病.	月刊糖尿病	15(4)	12-20.	2023
Fukui A, Takeshita K, Nakashima A, Maruyama Y, Tsuboi N, Hoshina T, Yokoo	The relation between proteinuria and the severity of COVID-19.	Clin Exp Nephrol.	28(3)	235-244	2024
Shimohata H, Usui J, Tawara-Iida T, Ebihara I, Ishizu T, Maeda Y, Kobayashi H, Numajiri D, Kaneshige A, Sega M, Yamashita M, Ohgi K, Maruyama H, Takayasu M, Hirayama K,	Study Group of the Ibaraki Dialysis Initiation Cohort Study. NT-pro BNP level at dialysis initiation is a useful biomarker for predicting hospitalization for ischemic heart disease.	Clin Exp Nephrol.	Epub ahead of print.		2024
Nishitani N, Kosaki K, Mori S, Matsui M, Sugaya T, Kuro-O M, Saito C, Yamagata K, Maeda S.	Association of Lower Extremity Muscle Strength and Function with Renal Resistive Index in Individuals with and without Chronic Kidney Disease.	Geriatrics (Basel).	8(6)	118	2023

Mathur M, et al.	A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.	N Engl J Med.	390(1)	20-31	2024
Okubo R, et al.	Health-related quality of life in 10 years long-term survivors of chronic kidney disease: a From-J study.	J Ren Nutr.	S1051-2276(23)	11:S1051-2276(23)	2023
Writing Group for the CKD Prognosis Consortium; Grams ME, et al.	Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.	JAMA.	330(13)	1266-1277	2023
Tasaki H, et al.	Synergistic effect of proteinuria on dipstick hematuria-related decline in kidney function: The Japan Specific Health Checkups (J-SHC) Study.	Clin Exp Nephrol.	Epub ahead of print.		2023
Nagai K, et al.	Weight Loss Improves Liver Dysfunction and Dipstick Proteinuria in Obesity: The Japan Specific Health Checkups Study.	JMA J.	6(3)	312-320	2023
Takahashi-Kobayashi M, Usui J, Kawanishi K, Saito C, Ebihara I, Yamagata K.	Adding Cases to the Study of Bucillamine-Associated Neural Epidermal Growth Factor-Like-Positive Membranous Nephropathy.	Kidney Int Rep.	8(8)	1698-1699	2023
Kosugi T, et al.	Trace proteinuria detected via dipstick test is associated with kidney function decline and new-onset overt proteinuria: the Japan Specific Health Checkups (J-SHC) Study.	Clin Exp Nephrol.	27(10)	801-808	2023

Kurasawa S, Yasuda Y, Kato S, Maruyama S, Okada H, Kashihara N, Narita I, Wada T, Yamagata K;	REACH-J CKD collaborators. Relationship between the lower limit of systolic blood pressure target and kidney function decline in advanced chronic kidney disease: an instrumental variable analysis from the REACH-J CKD cohort study.	Hypertens Res.	Epub ahead of print.		2023
Kosaki K, Park J, Matsui M, Sugaya T, Kuro-O M, Saito C, Yamagata K, Maeda S.	Elevated urinary angiotensinogen excretion links central and renal hemodynamic alterations.	Sci Rep.	13(1)	11518	2023
Calice-Silva V, Muenz D, Wong MMY, McCullough K, Charytan D, Reichel H, Robinson B, Stengel B, Massy ZA, Pecoits-Filho R; CKDopps Investigators.	International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care: is it time to review guideline	Lipids Health Dis.	22(1)	67	2023
Murano H, et al.	The effect of lifestyle on the mortality associated with respiratory diseases in the general population.	Sci Rep.	13(1)	8272	2023
蒲澤 佳子、伊藤 由美、田中 純太、成田 一衛	大規模コホート追跡による慢性腎臓病（CKD）の生活習慣リスク因子の解明	新潟県医師会報	877	7-8	2023
Wakasugi M, Yokoseki A, Wada M, Momotsu T, Sato K, Kawashima H, Nakamura K, Onodera O, Narita I.	Vegetable and Fruit Intake Frequency and Mortality in Patients With and Without Chronic Kidney Disease: A Hospital-Based Cohort Study.	J Ren Nutr.	33(4)	566-74.	2023
Shirai N, Yamamoto S, Osawa Y, Tsubaki A, Morishita S, Narita I.	Dynamic and static balance functions in hemodialysis patients and non-dialysis dependent CKD patients.	Ther Apher Dial.	27(3)	412-8	2023

Sato Y, Kabasawa K, Ito Y, Tsugane S, Nakamura K, Tanaka J, Narita I.	Association between Physical Activity in Rural Life and Sarcopenia in Community-Dwelling Middle-Aged and Older Japanese Adults: A Cross-	Tohoku J Exp Med.	261(4)	317-23	2023
Okubo R, Kondo M, Imasawa T, Saito C, Kai H, Tsunoda R, Hoshino J, Watanabe T, Narita I, Matsuo S, Makino H, Hishida A,	Health-related Quality of Life in 10 years Long-term Survivors of Chronic Kidney Disease: A From-J Study.	J Ren Nutr.			2023
Shirai N, Yamamoto S, Osawa Y, Tsubaki A, Morishita S, Sugahara T, Narita I.	Low muscle strength and physical function contribute to falls in hemodialysis patients, but not muscle mass.	Clin Exp Nephrol	28(1)	67-74	2024
Kitabayashi K, Yamamoto S, Narita I.	Appropriate Anthropometric Indices for Geriatric Nutritional Risk Index in Predicting Mortality in Older Japanese Patients: A Comparison of the Lorentz Formula and Body Mass Index.	Tohoku J Exp Med.			2024
Kabasawa H, Hosojima M, Narita I.	Questionnaire survey of the frequency of dietary intake during hemodialysis and the impact of COVID-19 in Japan.	Clin Exp Nephrol	28(3)	254-60.	2024
Wakasugi M, Narita I.	Higher participation rates for specific health checkups are associated with a lower incidence of treated ESKD in Japan.	Clin Exp Nephrol.	doi: 10.1007/s10157-023-02412-3.	Epub ahead of print.	2023
若杉 三奈子, 成田 一衛.	健康診断データを活用した地域レベルでのCKD 患者数の推計.	日腎会誌	65(5)	485-490	2023

若杉 三奈子, 成田 一衛.	腎硬化症による透析導入患者は、導入年末時での脳出血既往・喫煙率・過体重割合が高い	日腎会誌	65(8)	975-987	2023
若杉 三奈子, 成田 一衛.	近年の透析導入率の変化, 2006~2021.	日腎会誌	66(1)	333-342.	2024
猪阪 善隆	日本のCKD患者数の概算	日本医師会雑誌	7	In press	2024
Onishi Y, et al.	The Effect of Medical Cooperation in the CKD Patients: 10-Year Multicenter Cohort Study.	J Pers Med.	13(4)	582	2023 Mar 26
Osakabe Y, Taniguchi Y, Hamada Ode K, Shimamura Y, Inotani S, Nishikawa H, Matsumoto T, Horino T, Fujimoto S,	Clinical significance of amphiregulin in patients with chronic kidney disease.	Clin Exp Nephrol.	doi: 10.1007/s10157-023-02445-8.	Online ahead of print. PMID: 38402497	2024
Horino T, Osakabe Y, Ishihara M, Nakajima K, Terada Y.	Nephrotic syndrome caused by IgA vasculitis flare up following COVID-19 vaccination.	QJM	116(7)	556-558	2023
Hatakeyama Y, Horino T, Yasui S, Komori M, Terada Y, Okuhara Y.	Incidence of acute kidney injury and decreased estimated glomerular filtration rate according to the site of cancer.	Clin Exp Nephrol.	27(3)	262-271	2023
Hara A, et al; LICENSE study group	Effect of Low-Density Lipoprotein Apheresis on Quality of Life in Patients with Diabetes, Proteinuria, and Hypercholesterolemia	Blood Purif	52(4)	373-381	2023
Miyasato Y, Hanna RM, Mukoyama M, et al.	Associations of interdialytic weight gain in the long intervals with mortality and residual kidney function decline.	Hemodial Int	27 (3)	326-338	2023
Fujimoto D, Kuwabara T, Mukoyama M.	Need to continue or discontinue RAS inhibitors as CKD stage advances? Any alternative?	Hypertens Res	46 (8)	2048-2050	2023

Miyasato Y, Mukoyama M.	More delicate blood pressure management in patients with chronic kidney disease: is lower not the better?	Hypertens Res	46 (12)	2757-2758	2023
Mukoyama M, Kuwabara T.	Pre-dialysis blood pressure and cardiovascular mortality in Japan: need for much stricter control?	Hypertens Res	47 (3)	811-812	2024
栗原孝成、向山政志	ARNI（サクビトリルバルサルタン）の高血圧治療戦略における位置づけ.	カレントセラピー	41 (5)	470-475	2023
栗原孝成	総説「がん薬物療法時の腎障害診療ガイドライン2022」の概説	日本病院薬剤師雑誌	59 (9)	940-943	2023
國友理恵, 要 伸也	透析導入直後に現れやすい症状とその治療は?	月間薬事	65 (12)	2405-2406	2023
Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S.	Inpatient multidisciplinary care can prevent deterioration of renal function in patients with chronic kidney disease: a nationwide cohort study.	Front Endocrinol (Lausanne)	14	1180477	2023
Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S	Examine the optimal multidisciplinary care teams for patients with chronic kidney disease from a nationwide cohort study.	Kidney Res Clin Pract			In press
Nyma Z, et al.	Evaluating the associations between compliance with CKD guideline component metrics and renal outcomes.	Sci Rep	14	11481	2024
Okada H, et al	Development of a prognostic risk score to predict early mortality in incident elderly Japanese hemodialysis patients.	PLoS One	19	e0302101	2024

岡田浩一	特集：病診連携と多職種で取り組む日本のCKD対策 CKDの疾患概念とその臨床的重要性	日医会誌	153	385-388	2024
岡田浩一	特集：CKD対策の現在地 日本腎臓病協会・CKD対策研究班の協力体制とCKD対策	日腎会誌	(in press)	(in press)	(in press)
Kitai T, Maruyama S, Kuwahara K, Tamura K, Kinugawa K, Kashihara N.	Establishing Cross-Specialty Expert Consensus on the Optimal Management of Hyperkalemia in Patients With Heart Failure and Chronic Kidney Disease.	Circ J.	89(4)	470-478	2025
Kashihara N, Okada H, Suzuki Y, et al.	Efficacy and safety of patiromer for hyperkalemia: a randomized, placebo-controlled phase 3 study.	Clin Exp Nephrol.	Online ahead of print		2025
Johannes CB, Ziemiecki R, Pladivall-Vila M, et al.	Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study.	Diabetes Ther.	16(2)	205-226	2025
Mondal R, Rituraj B, Kitaoka K, et al.	Oral microbiome alpha diversity and all-cause, cardiovascular, and non-cardiovascular mortality in US adults: Evidence from the NHANES 2009-2019.	Atherosclerosis.	401	119074	2025
Pollock C, Carrero JJ, Kanda E, et al.	Baseline Characteristics of the DISCOVER CKD Prospective Cohort.	Adv Ther.	42(3)	1393-1418	2025
Perkovic V, Barratt J, Rovina B, Kashihara N, et al.	Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.	N Engl J Med.	392(6)	531-543	2025
Ohashi M, Ishikawa Y, Arai S, et al.	Comparative analysis of kidney function prediction: traditional statistical methods vs. deep learning techniques.	Clin Exp Nephrol.	Online ahead of print.		2025

Asahi K, Konta T, Tamura K, et al.	The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes.	J Diabetes Investig.	16(1)	108-119	2025
Konta T, Asahi K, Tamura K, et al.	The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese non-diabetic patients.	Clin Exp Nephrol.	Online ahead of print.		2024
Heerspink HJL, Perkovic V, Tuttle KR, et al.	Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial.	J Am Soc Nephrol.	35(12)	1726-1736.	2024
Shimamoto S, Nakahara T, Yamada S, Nagasu H, et al.	Association between proteinuria and mineral metabolism disorders in chronic kidney disease: the Japan chronic kidney disease database extension (J-CKD-DB-Ex).	Sci Rep.	28(8)	784-792	2024
Umebayashi R, Matsuoaka-Uchiyama N, Sugiyama H, et al.	The Change in Public Perception and Knowledge Acquisition Methods of Chronic Kidney Disease Among General Population in Okayama Prefecture, Japan.	Diseases.	12(11)	268	2024
Kishi S, Kadoya H, Kashiwara N.	Treatment of chronic kidney disease in older populations.	Nat Rev Nephrol.	20(9)	586-602	2024
Aoki R, Nihei Y, Matsuzaki K, et al.	Gross Hematuria after the COVID-19 mRNA Vaccination: Nationwide Multicenter Prospective Cohort Study in Japan.	Kidney360.	5(9)	1322-1332	2024
Sugawara Y, Kanada E, Hamano T, et al.	Guidelines for clinical evaluation of chronic kidney disease in early stages : AMED research on regulatory science of pharmaceuticals and medical devices.	Clin Exp Nephrol.	28(9)	847-865	2024

Pollock C, Carrero JJ, Kanda E, et al.	The Lived Experience of Patients with Chronic Kidney Disease: Insights From DISCOVER CKD.	Am J Nephrol.	55(6)	618-628	2024
Fishbane S, Carrero JJ, Kumar S, et al.	Hyperkalemia Burden and Treatment Pathways in Patients with CKD: Findings From the DISCOVER CKD Retrospective Cohort.	Kidney360.	5(7)	974-986	2024
Kanaoka T, Waki H, Yano Y, Nagasu H, et al.	J - CKD - DB investigators. Factors affecting the sodium-glucose cotransporter 2	Diabetes Obes Metab.	26(7)	2905-2914	2024
Nangaku M, Herrington WG, Goto S, et al.	Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY.	Clin Exp Nephrol.	28(6)	588-595	2024
Kitaoka K, Yano Y, Nagasu H, et al.	Kidney outcomes of SGLT2 inhibitors among older patients with diabetic kidney disease in real-world clinical practice: the Japanese Chronic Kidney Disease Database Ex.	BMJ Open Diabetes Res Care.	12(3)	e004115	2024
Waki K, Nara M, Enomoto S, et al.	Effectiveness of DiabetesPlus, a self-management support system for diabetic kidney disease: Randomized controlled trial.	NPJ Digit Med.	7(1)	104	2024
Yusei O, et al.	A case series of Fabry diseases with CKD in Japan.	Clin Exp Nephrol.	28(5)	404-408	2024
柏原 直樹	NPO法人日本腎臓病協会の取り組み.	日本医師会雑誌	153(4)	393-396	2024
岡田浩一, 柏原直樹, 栗原孝成, 小林一雄.	日本のCKD対策に今, 何が必要か.	日本医師会雑誌	153(4)	369-382	2024
角谷裕之, 柏原直樹.	今, なぜ, 透析医療と臨床倫理なのか? AMED CKMガイド2022から日本透析医学会の提言2020を倫理的に読み解く.	臨床透析	40(10)	1261-1265	2024

柏原直樹.	高齢化社会における腎臓病診療.	日本腎臓学会誌	66(2)	351-356	2024
Usui J, Hirayama K, Kobayashi M, Suzuki S, Ebihara I, Nishikii K, Mase K, Hirayama A, Saito C, Goto M, Koyama A, Yamagata K.	Randomized Prospective Controlled Open-labeled Trial of Cyclosporine with/without Low-dose Oral Corticosteroids in Idiopathic Membranous Nephropathy in Adults with Nephrotic Syndrome.	Intern Med.	Epub ahead of print.		2025
Nakamura H, Okubo R, Kumagai M, Anayama M, Maki Y, Tamura K, Nagasawa M, Okada H, Maruyama S, Hoshino J, Wada T, Narita I, Yamagata K.	Exploring factors associated with Kidney Disease Quality of Life in patients with advanced chronic kidney disease: the Reach-J CKD cohort study.	Clin Exp Nephrol.			2025
Otake Y, Watanabe T, Konta T, Watanabe M, Asahi K, Yamagata K, Fujimoto S, Tsuruya K, Narita I, Kasahara M, Shibagaki Y, Iseki K, Moriyama T, Kondo M, Watanabe T.	Macrocytic anemia, kidney dysfunction, and mortality in general population: Japan specific health checkup study.	Sci Rep.	14(1)	32005	2024
Tsunoda R, Kume K, Kagawa R, Sakanuki M, Kitagawa H, Mase K, Yamagata K.	Machine-learning-based identification of patients with IgA nephropathy using a computerized medical billing database.	PLoS One.	19(12)	e0312915	2024
Okubo R, Ohigashi T, Kondo M, Tsunoda R, Kai H, Saito C, Hoshino J, Okada H, Narita I, Maruyama S, Wada T, Yamagata K.	Associations of anemia and iron deficiency with health-related quality of life in patients with chronic kidney disease stage G3b-5 in Japan: sub analysis of the Reach-J CKD cohort study.	BMC Nephrol.	25(1)	414	2024

Hoshino J, Ohigashi T, Tsunoda R, Ito Y, Kai H, Saito C, Okada H, Narita I, Wada T, Maruyama S, Pisoni R, Pecoits-Filho R, Yamagata K.	Physical activity and renal outcome in diabetic and non-diabetic patients with chronic kidney disease stage G3b to G5.	Sci Rep.	14(1)	26378	2024
Kosugi T, et al.	Association of body indices with mortality in older population: Japan Specific Health Checkups (J-SHC) Study.	J Am Geriatr Soc.	Epub ahead of print.		2024
Takahashi-Kobayashi M, Kawanishi K, Usui J, Yamazaki S, Seshan SV, Yamagata K.	Does old-to-young kidney transplantation rejuvenate old donor kidneys?	Histol Histopathol.	Epub ahead of print.		2024
Kosugi T, et al.	Serum High-Density Lipoprotein Cholesterol Levels and the Risk of Kidney Function Decline: The Japan Specific Health Checkups (J-SHC) Study.	J Atheroscler Thromb.	Epub ahead of print.		2024
Akiyama T, et al.	Serum calciprotein particle-to-phosphate ratio as a predictor of cardiovascular events in incident hemodialysis patients.	Ther Apher Dial.	Epub ahead of print.		2024
Kanauchi N, Saito C, Nagai K, Yamada K, Kai H, Watanabe T, Narita I, Matsuo S, Makino H, Hishida A, Yamagata K.	Effective method for life-style modifications focused on dietary sodium intake in chronic kidney disease: sub-analysis of the FROM-J study.	BMC Nephrol.	25(1)	274	2024

Miura M, Kohzuka K, Ii M, Saito C, Seki M, Takai S, Sugaya H, Koyama S, Matsui Y, Sakuma T, Ito O, Yamagata K.	Systemic Capillary Responses to Acute Exercise in Hypertensive Seniors: Insights from a Single-Center Pilot Study.	J Clin Med.	13(10)	2818	2024
Tamaki H, et al.	Pulse pressure modifies the association between diastolic blood pressure and decrease in kidney function: the Japan Specific Health Checkups Study.	Clin Kidney J.	17(6)	sfaf152	2024
Mori S, Kosaki K, Matsui M, Tanahashi K, Sugaya T, Iwazu Y, Kuro-O M, Saito C, Yamagata K, Maeda S.	Estimated proximal tubule fluid phosphate concentration and renal tubular damage biomarkers in early stages of chronic kidney disease.	J Ren Nutr.	Epub ahead of print.		2024
Prasad P, Yamagata K.	One Size Doesn't Fit All: Revisiting the Threshold, Target, and Type of Erythropoietin-Stimulating Agent Therapy in Anemia of CKD.	Kidney Int Rep.	9(7)	1954-1956	2024
Sofue T, Matsuzawa R, Nishiwaki H, Tsuchida Y, Kosaki K, Honshino J, Narita I, Yamagata K.	Exercise instruction during haemodialysis treatment after changes to the insurance regime: a nationwide questionnaire survey in Japan.	Sci Rep.	14(1)	9171	2024
Matsumoto A, et al.	Cigarette smoking and progression of kidney dysfunction: a longitudinal cohort study.	Clin Exp Nephrol.	Epub ahead of print.		2024
Ishii R, et al.	Renal Hemodynamic and Functional Changes in ADPKD Patients.	Kidney360.	5(5)	724-731	2024

Imasawa H, et al.	Comprehensive review of mitochondrial nephropathy—a renal phenotype in mitochondrial disease: causative genes, clinical and pathological features, diagnosis, prognosis, and treatment.	Clin Exp Nephrol.	29	39-56	2025
今澤俊之	ミトコンドリア腎症	日内会誌	113	1439-1444	2024
Habuka M, Hosojima M, Yata Y, Kurumada K, Yamagiwa M, Yonezawa M, et al.	Fanconi syndrome with acute proximal tubular injury induced by a dietary supplement containing benfotiamine: a case series report.	BMC Nephrol.	25	446	2024
Wakasugi M, Gotō S.	An increasing trend of overweight and obesity in the Japanese incident end-stage kidney disease population.	Nephrology (Carlton).	29	884-894	2024
Mitsuboshi S, Morizumi M, Kotake K, Kaseda R, Narita I.	Individual dipeptidyl peptidase-4 inhibitors and acute kidney injury in patients with type 2 diabetes: A systematic review and network meta-analysis.	Basic Clin Pharmacol Toxicol.	135	71-80	2024
Mitsuboshi S, Morizumi M, Kotake K, Kaseda R, Narita I.	Urate-Lowering Drugs and Muscle Injury: A Systematic Review and Network Meta-Analysis.	J Clin Pharmacol.	64	288-299	2024
Shirai N, Yamamoto S, Osawa Y, Tsubaki A, Morishita S, Murayama T, et al.	Protein intake and its relationship with frailty in chronic kidney disease.	Clin Exp Nephrol.	28	447-453	2024
Shirai N, Yamamoto S, Osawa Y, Tsubaki A, Morishita S, Sugahara T, et al.	Low muscle strength and physical function contribute to falls in hemodialysis patients, but not muscle mass.	Clin Exp Nephrol.	28	67-74	2024

Wakasugi M, Narita I.	Trends in the Incidence of Renal Replacement Therapy Due to Rapidly Progressive Glomerulonephritis in Japan, 2006-2021.	Intern Med.	63	2751-2755	2024
Wakasugi M, Yokoseki A, Wada M, Yoshino T, Momotsu T, Sato K, et al.	Cataract Surgery and Chronic Kidney Disease: A Hospital-based Prospective Cohort Study.	Intern Med.	63	1207-1216	2024
Kabasawa K, Takachi R, Hosojima M, Komata T, Nakamura K, Sawada N, et al.	Association of Protein Intake With Discordance Between Cystatin C- and Creatinine-Based Estimated Glomerular Filtration Rates in Community-dwelling Japanese Adults.	J Ren Nutr.	(in press)	(in press)	(in press)
猪阪 善隆	日本のCKD患者数の概算	日本医師会雑誌	7	384	2024
猪阪 善隆	大阪府内科医会会員におけるCKD関連新規治療薬に関する実態調査	大阪府内科医会誌	33	76-82	2024
Yasui S, Horino T, Mitani K, Terada Y, Okuhara Y, Hatakeyama Y.	Effect of age, sex, and chronic kidney disease on urinary creatinine excretion in Japanese patients.	Clin Exp Nephrol.	29	83-90	2025
Hatakeyama Y, Horino T, Yasui S, Terada Y, Okuhara Y.	Differences in characteristics and risk factors for acute kidney injury between elderly and very elderly patients: a retrospective review.	Clin Exp Nephrol.	28	1097-1110	2024
Horino T, Inotani S, Komori M, Ohnishi H, Terada Y.	Neuropsychiatric Systemic Lupus Erythematosus in a Patient with Pancytopenia and Chronic Schizophrenia Requiring Hospitalisation.	Intern Med.	64	147-151	2025
Osakabe Y, et al.	Clinical significance of amphiregulin in patients with chronic kidney disease.	Clin Exp Nephrol.	28	421-430	2024

Funakoshi S, et al.	Hypopituitarism due to CNS Aspergillus Infection.	Intern Med.	63	2953-2959	2024
Kuwabara T, et al.	Survey of renal Biopsy registry database J. and Anticancer drug therapy in Japan (SUBARU-J study) .	Clin Kidney J.	17	327	2024
Mukoyama M, Kuwabara T.	Pre-dialysis blood pressure and cardiovascular mortality in Japan: Need for much stricter control?	Hypertens Res	47	811-812	2024
Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S	Examine the optimal multidisciplinary care teams for patients with chronic kidney disease from a nationwide cohort study.	Kidney Res Clin Pract	44	249-264	2025
Sada KE, Nagasaka K, Kaname S, Nango E, Kishibe K, Dobashi H, Hiromura K, Kawakami T, Bandono M, Wada T, Arimura K, Murakawa Y, Harigai M	Clinical practice guidelines of the Japanese Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of microscopic polyangiitis and granulomatosis with polyangiitis: The 2023 update-secondary publication.	Mod Rheumatol	34	559-567	2024
Sada KE, Nagasaka K, Kaname S, Higuchi T, Furuta S, Nanki T, Tsuboi N, Amamoto K, Dobashi H, Hiromura K, Bandono M, Wada T, Arimura Y, Maki no H, Harigai M.	Evaluation of Ministry of Health, Labour and Welfare diagnostic criteria for antineutrophil cytoplasmic antibody-associated vasculitis compared to ACR/EULAR 2022 classification criteria.	Mod Rheumatol	34	551-558	2024
Maruyama S, Ikeda Y, Kaname S, Kato N, Matsumoto M, Ishikawa Y, Shimono A, Miyakawa Y, Nanpaku M, Shibagaki Y, Okada H.	Ecilizumab for adult patients with atypical haemolytic-uraemic syndrome: full dataset analysis of Japanese post-marketing surveillance.	J Nephrol	37	2181-2190	2024

Nagase M, et al.	Glomerular endothelial cell receptor adhesion G-protein-coupled receptor F5 (ADGRF5) and the integrity of the glomerular filtration barrier.	J Am Soc Nephrol	35	1366-1380	2024
Kawazoe M, et al.	Nationwide epidemiological survey of polyarteritis nodosa in Japan in 2020.	Mod Rheumatol	34	1284-1287	2024
Katsumata Y, et al.	Comparison of different ANCA detection methods in a predominantly MPO-ANCA-associated vasculitis cohort.	Immunol Med	48	47-57	2025
Kaname S, Ong M-L, Mathiasc J, Gattad F, Lawer L, Wang Y	Outcomes in patients with thrombotic microangiopathy associated with a trigger following plasma exchange: a systematic literature review.	Transfus Apher Sci	64	104048	2024
要 伸也	CKD対策における多職種ケアの重要性. 特集：病診連携と多職種で取り組む日本のCKD対策.	日本医師会雑誌	153	407-411	2024
要 伸也	慢性腎臓病に対するチーム医療と慢性腎臓病透析予防指導管理料の新設.	日本透析医学会雑誌	39	472-479	2024
中川 直樹	CKD対策における健診受診と受診勧奨の重要性	日本医師会雑誌	153巻4号	413-416	2024
Matsuoka-Uchiyama N, et al.	The association of fasting triglyceride variability with renal dysfunction and proteinuria in medical checkup participants.	Clin Exp Nephrol	Epub ahead of print.	Epub ahead of print.	Epub ahead of print.
Umebayashi R, Matsuoka-Uchiyama N, Sugiyama H, Shikata K, Kashiwara N, Makino H, Wada J, Uchida HA.	The Change in Public Perception and Knowledge Acquisition Methods of Chronic Kidney Disease Among General Population in Okayama Prefecture, Japan.	Diseases	12(11)	268	2024

旭浩一	日本のCKD対策の進捗状況と展望	日本医師会雑誌 153: 397-	153	397-401	2024
Kuwabara T, Miyasato Y, Mukoyama M, et al.	Survey of renal Biopsy registry database and Anticancer drug therapy in Japan (SUBARU-J study).	Clin Kidney J.	17 (12)	sfae327	2024
Yamamoto T, Kasahara M, Mukoyama M, et al.	Multicenter randomized controlled trial of intensive uric acid lowering therapy for CKD patients with hyperuricemia: TARGET-UA.	Clin Exp Nephrol.	28 (8)	764-772	2024
Mukoyama M.	Fetal origins of adult hypertension and renal injury: an epigenetic memory matter?	Hypertens Res	47 (10)	2942-2944	2024
Mukoyama M.	Treatment with a mineralocorticoid receptor blocker esaxerenone on top of the first-line therapy: promise in uncontrolled hypertension.	Hypertens Res	47 (12)	3492-3493	2024
Morita H, Abe M, Mukoyama M, et al.	Resistance exercise has a sufficient antihypertensive effect comparable to aerobic exercise in hypertensive patients: a meta-analysis of randomized controlled trials.	Hypertens Res	48 (2)	733-743	2025
Suematsu Y, Morita H, Mukoyama M, et al.	Differences in the effects of exercise on blood pressure depending on the physical condition of the subject and the type of exercise: a systematic review and meta-analysis.	Hypertens Res	48 (2)	720-732	2025

Mayne KJ, Sarde ll RJ, Staplin N, et al.	Frailty, Multimorbid ity, and Polypharmac y: Exploratory Analy ses of the Effects o f Empagliflozin from the EMPA-KIDNEY Tri al.	Clin J Am So c Nephrol	19	1119-1129	2024
Nakahara E, Wak i K, Kurasawa H, et al.	Predicting rapid dec line in kidney funct ion among type 2 dia betes patients: A ma chine learning appro ach.	Heliyon	11	e40566	2024
Erickson RL, Ka math N, Iyengar A, et al.	Disparities in kidney care in vulnerable populations: A mult inational study from the ISN-GKHA.	PLOS Glob Pu blic Health	4	e0004086	2024
Azegami T, Kane ko H, Okada A, e t al.	Association of Estim ated Glomerular Fil tration Ratio with th e Incidence of Sleep Apnea Syndrome.	Sleep	[Online ahead of pri nt]	[Online ahead of pri nt]	[Online ahead of pri nt]
Nishi H, Nangak u M, Sofue T, et al.	N-terminal pro-brain natriuretic peptide il and cardiorenal out come in patients wit h anaemia in chronic kidney disease.	ESC Heart Fa il	[Online ahead of print]	[Online ahead of print]	[Online ahead of print]
Kotwal SS, Perk ovic V, Jardine MJ, et al.	The Global Kidney Pa tient Trials Network and the CAPTIVATE P latform Clinical Tri al Design: A Trial P rotocol.	JAMA Netw Op en	7	e2449998	2024
Garcia P, Stras ma AK, Wijewick rama E, et al.	Regional hotspots fo r chronic kidney dis ease: A multination al study from the ISN -GKHA.	PLOS Glob Pu blic Health	4	e0004014	2024
Nkunu V, Tungsa nga S, Diongole HM, et al.	Landscape of kidney replacement therapy provision in low- an d lower-middle incom e countries: A multi national study from the ISN-GKHA.	PLOS Glob Pu blic Health	4	e0003979	2024

Okada A, Aso S, Kurakawa KI, et al.	Adding biomarker change information to the kidney failure risk equation improves predictive ability for dialysis dependency in eGFR <30 ml/min/1.73 m ² .	Clin Kidney J	17	sfae321	2024
Wainstein M, Tiv S, Arruebo S, et al.	Global Policy and Advocacy Initiatives for Improving Kidney Care: Report from the 2023 ISN-GKHA Study.	Kidney360	[Online ahead of print]	[Online ahead of print]	[Online ahead of print]
Judge PK, Tuttle KR, Staplin N, et al.	The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicirostat (BI 690517): a rationale for the EASi-KIDNEY trial.	Nephrol Dial Transplant	[Online ahead of print]	[Online ahead of print]	[Online ahead of print]
Herrington WG, Staplin N, Agrawal N, et al.	Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.	N Engl J Med	[Online ahead of print]	[Online ahead of print]	[Online ahead of print]
Wainstein M, Nandhu Y, Viecelli A, et al.	A global snapshot on health systems capability for detection, monitoring, and management of acute kidney injury: A multinational study from the ISN-GKHA.	PLOS Glob Public Health	4	e0003823	2024
Okpechi IG, Levin A, Tungsanga S,	Progress of nations in the organisation of, and structures for, kidney care delivery between 2019 and 2023: cross sectional survey in 148 countries.	BMJ	387	e079937	2024
Ekrikpo UE, Davidson B, Calice-Silva V, et al.	Structures for quality assurance and measurements for kidney replacement therapies: A multinational study from the ISN-GKHA.	Nephrology	29	873-883	2024

Ko T, Kaneko H, Suzuki Y, et al.	Dose-dependent association between estimated glomerular filtration rate and the subsequent risk of depression: An analysis of a nationwide epidemiological dataset.	Eur J Clin Invest	55	e14322	2025
Mayne KJ, Sardehlil RJ, Staplin N, et al.	EMPA-KIDNEY Collaborative Group. Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.	Nephrol Dial Transplant	[Online ahead of print]	[Online ahead of print]	[Online ahead of print]
See E, Ethier I, Cho Y, et al.	Dialysis Outcomes Across Countries and Regions: A Global Perspective From the International Society of Nephrology Global Kidney Health Atlas Study.	Kidney Int Rep	9	2410-2419	2024
Jimba T, Kaneko H, Azegami T, et al.	Body weight change associated kidney outcomes of sodium-glucose cotransporter new users.	Diabetes Obes Metab	26	4535-4543	2024
Suzuki Y, Kaneko H, Okada A, et al.	Kidney outcomes with SGLT2 inhibitor vs. DPP4 inhibitor use in older adults with diabetes.	Nephrol Dial Transplant	[Online ahead of print]	[Online ahead of print]	[Online ahead of print]
Kato S, Wang J, Onishi Y, Nangaku M.	Association between magnesium, erythropoietin resistance and mortality: the Japanese Dialysis Outcomes and Practice Patterns Study (J-DOPPS).	Clin Kidney J	17	sfaf153	2024
Hanafusa N, Henrich L, Bieber B, et al.	Erythropoiesis-stimulating agent hyporesponsiveness was associated with worse survival of hemodialysis patients independent of the serum ferritin level.	Ther Apher Dial	[Online ahead of print]	[Online ahead of print]	[Online ahead of print]

Mayne KJ, Sarde ll RJ, Staplin N, et al.	EMPA-KIDNEY Collaborative Group. Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.	Clin J Am Soc Nephrol	[Online ahead of print]	[Online ahead of print]	[Online ahead of print]
Azegami T, Kaneko H, Okada A,	Significance of eGFR and proteinuria for cardiovascular disease in individuals beyond 85 years.	Nephrol Dial Transplant	[Online ahead of print]	[Online ahead of print]	[Online ahead of print]
Heerspink HJL, Cherney D, Abdul Gafor AH, et al.	Effect of Avenciguat on Albuminuria in Patients with CKD: Two Randomized Placebo-Controlled Trials.	J Am Soc Nephrol	35	1227-1239	2024
Ghimire A, Shah S, Chauhan U, et al.	Global variations in funding and use of hemodialysis accesses: an international report using the ISN Global Kidney Health Atlas.	BMC Nephrol	25	159	2024
Higashihara T, Odawara M, Nishi H, et al.	Uremia Impedes Skeletal Myocyte Myomixer Expression and Fused Genic Activity: Implication for Uremic Sarcopenia.	Am J Pathol	194	759-771	2024
Lowe-Jones R, Eithier I, Fisher LA, et al.	Capacity for the management of kidney failure in the International Society of Nephrology North America and the Caribbean region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).	Kidney Int Suppl	13	97-109	2024
Pippas M, Alfano G, Kelly DM, et al.	Regional Board and ISN-GKHA Team Authors. Capacity for the management of kidney failure in the International Society of Nephrology Western Europe region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).	Kidney Int Suppl	13	136-151	2024

Wing-Shing Fung W, Park HC, et al.	Regional Board and ISN-GKHA Team Authorship. Capacity for the management of kidney failure in the International Society of Nephrology North and East Asia region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).	Kidney Int Suppl	S13	97-109	2024
Calice-Silva V, Neyra JA, Ferrero Fuentes A, et al.	Regional Board and ISN-GKHA Team Authorship. Capacity for the management of kidney failure in the International Society of Nephrology Eastern and Central Europe region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).	Kidney Int Suppl	S13	29-42	2024
Karam S, Amouzei A, Alshamsi IR, et al.	Capacity for the management of kidney failure in the International Society of Nephrology Middle East region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).	Kidney Int Suppl	S13	57-70	2024
Francis A, Wainstein M, Irish G, et al.	Capacity for the management of kidney failure in the International Society of Nephrology Oceania and South East Asia (OSEA) region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).	Kidney Int Suppl	S13	110-122	2024

Prikhodina L, Komissarov K, Bulanov N, et al.	Capacity for the management of kidney failure in the International Society of Nephrology Newly Independent States and Russia region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).	Kidney Int Suppl	S13	71-82	2024
Wijewickrama E, Alam MR, Bajpai D, et al.	Regional Board and ISN-GKHA Team Authors. Capacity for the management of kidney failure in the International Society of Nephrology South Asia region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).	Kidney Int Suppl	S13	123-135	2024
Tannor EK, Davidson B, Nlandu Y, et al.	Regional Board and ISN-GKHA Team Authors. Capacity for the management of kidney failure in the International Society of Nephrology Africa region: report from the 2023 ISN Global Kidney Atlas (ISN-GKHA).	Kidney Int Suppl	S13	12-28	2024
Nangaku M, Ueta K, Nishimura K, et al.	Factors affecting responsiveness of vadastat in patients with anemia associated with chronic kidney disease: a post-hoc subgroup analysis of Japanese phase 3 randomized studies.	Clin Exp Nephrol	28	391-403	2024
Suzuki Y, Kaneko H, Nagasawa H, et al.	Comparison of estimated glomerular filtration rate change with sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists among people with diabetes: A propensity-score matching study.	Diabetes Obes Metab	26	2422-2430	2024

Sakashita M, Hashimasaaki Y, Okimura R, et al.	Serum myostatin at dialysis initiation may predict 1-year mortality and hospitalization.	Nephron	148	544-552	2024
Bello AK, Okpechi IG, Levin A, et al.	ISN-GKHA Group. An update on the global disparities in kidney disease burden and care across world countries and regions.	Lancet Glob Health	12	e382-e395	2024
Wanner C, Nankaku M, Kraus BJ, et al.	How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial.	Nephrol Dial Transplant	39	1504-1513	2024
Tuttle KR, Hauske SJ, Canziani ME, et al.	Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.	Lancet	403	379-390	2024
EMPA-KIDNEY Collaborative Group.	Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.	Lancet Diabetes Endocrinol	12	51-60	2024
Ikejiri K, Suzuki T, Muto S, et al.	Effects of NRF2 polymorphisms on safety and efficacy of bardoxolone methyl: subanalysis of TSUBAKI study.	Clin Exp Nephrol	28	225-234	2024
Okada A, Yamaguchi S, Imaizumi T, et al.	Modification effects of albuminuria on the association between kidney function and development of anemia in diabetes.	J Clin Endocrinol Metab	109	1012-1032	2024